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To assess whether the combined evaluation of total Sequen-
tial Organ Failure Assessment (t-SOFA) score and pro- and
anti-inflammatory cytokine profiles early after left ventricular
assist device (LVAD) implant discriminates patients at high
risk for multiple organ failure syndrome (MOFS) in the first
month post-LVAD, we analyzed plasma interleukin (IL)-6,
IL-8, IL-10, IL-1ra, IL-1, tumor necrosis factor- (TNF-),
and urine neopterin levels before (day 0) and at 4 hours, 1, 3,
7, 14, and 30 days after LVAD implant in 23 recipients. Eight
patients died of MOFS between days 7 and 30 (nonsurvivors).
At preimplant, only blood urea nitrogen and age were higher
in nonsurvivors than survivors. At 4 hours, IL-8, IL-10, and
IL1-ra levels were higher in nonsurvivors than in survivors;
t-SOFA was also higher and peaked on day 3 in nonsurvivors.
Only IL-8 levels on day 1 were significantly associated with a
t-SOFA>10 on day 3 (odds ratio 1.10, 95% confidence interval
1.01–1.21, p  0.04). Neopterin, marker of monocyte activa-
tion, increased significantly only in nonsurvivors (p < 0.001).
These findings suggest that an activated inflammatory system
soon after LVAD implant is implicated in MOFS development.
Early monitoring of inflammatory mediators and t-SOFA score
may be a valuable tool for outcome prediction in LVAD recip-
ients. ASAIO Journal 2010; 56:313–318.
Left ventricular assist device (LVAD) implant in end-stage
heart failure (ESHF) has proven effective as bridge to heart
transplantation (HT) by allowing recovery of adequate cardio-
vascular hemodynamic function. However, current 1-year sur-
vival rates of LVAD patients range approximately from 50% to
80%.1–3 The death hazard is highest during the first month after
LVAD implant, multiple organ failure syndrome (MOFS) being
the major cause of death.
The development of MOFS and its impact on the risk of
mortality in the intensive care unit (ICU) after cardiac surgery
have been described using the Sequential Organ Failure As-
sessment (SOFA) scoring system.4,5 Multiple organ failure syn-
drome is influenced by the degree of the immunoinflammatory
response, independent of the presence of infection. In LVAD
patients, liver dysfunction was shown to be associated to the
progressive release of inflammatory mediators,6 such as inter-
leukin (IL)-6, IL-8, and C-reactive protein (CRP). In the setting
of trauma or severe acute pancreatitis, early release of anti-
inflammatory cytokines has been detected in patients at high
risk for MOFS development.7,8 The impact of an early inflam-
matory response on MOFS development after LVAD implant
still needs to be elucidated.
To assess whether the early postimplant release of pro- and
anti-inflammatory cytokines would discriminate LVAD recipi-
ents at high risk for MOFS at 1 month, we assessed the profiles
of pro- and anti-inflammatory mediators by serial postopera-
tive monitoring and the changes in total SOFA (t-SOFA) score
in LVAD recipients during the first postoperative month.
Materials and Methods
In the study, we included 23 patients with ESHF, not ame-
nable to recovery by pharmacological or conventional surgical
therapy, who underwent LVAD implantation as bridge to HT
according to guideline indications for mechanical support.9 In
22 patients, continuous flow pumps were implanted: 8 De
Bakey (MicroMed, Houston, TX), 6 Incor (Berlin Heart GmbH,
Berlin, Germany), 4 HeartMateII (Thoratec, Pleasanton, CA),
and 4 Levitronix (Levitronix LLC, Waltham, MA) LVADs. A
pulsatile flow pump Novacor LVAD (World Heart Inc., Oak-
land, CA) was implanted in one patient.
The hemodynamic parameters, cardiac index, pulmonary
capillary wedge pressure, right atrial pressure, and mixed ve-
nous oxygen saturation, were measured by pulmonary artery
Swan-Ganz catheter. Left ventricular ejection fraction was quan-
tified by transesophageal echocardiography. Hemodynamic and
echocardiography were assessed preoperatively, before anesthe-
sia induction, at 4 hours and 1, 3, and 7 days after weaning
from cardiopulmonary bypass (CPB). We calculated the t-
SOFA score according to Pa¨tila¨ et al.4 from preimplant to 1
week after surgery. In sedated patients, the neurological score
was computed retrospectively, when sedatives were stopped
or alternatively, after their temporary discontinuation.
We measured plasma IL-6, IL-8, IL-10, IL-1, tumor necrosis
factor- (TNF-), IL-1 receptor antagonist (IL-1ra), serum CRP
(sCRP), and urine neopterin concentrations serially from day 0
to day 7 and subsequently at 14 and 30 days since LVAD
implant. Plasma cytokine levels were measured according to
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the methods of the manufacturer of the enzyme-linked immu-
nosorbent assays (R&D Systems, Minneapolis, MN, for IL-6, IL-8,
IL-10, and IL-1ra; Cayman, Ann Arbor, MI, for TNF- and IL-1),
whereas sCRP concentrations were measured using a Roche/
Hitachi 917 Analyzer by high-sensitive immunonephelometric
method (Roche Diagnostic GmbH, Mannheim, Germany).
Urinary neopterin levels were measured by an isocratic high
performance liquid chromatography (HPLC) method and were
normalized by urine creatinine concentrations (Neo/Cr).
Briefly, urine samples, stored at 20°C, were thawed and
centrifuged; the supernatant was then adequately diluted with
chromatographic mobile phase (15 mM of K2HPO4, pH 3.0).
Neopterin and creatinine levels were measured using a Kon-
tron instrument (pump 422-S, autosampler 465) coupled to a
fluorimetric detector (JASCO FP-1520, ex  355 nm and at
em  450 nm) for neopterin detection and to a UV-VIS
detector (BIO-RAD 1706,   240 nm) for creatinine determi-
nation. Neopterin and creatinine separations were performed
at 50°C on a 5-m Discovery C18 analytical column (250 
4.6 mm ID, Supelco, Sigma-Aldrich, Bellofante, PA) at flow
rate of 0.9 ml/min. The calibration curves were linear over the
range of 0.125–1 mol/L and 1.25–10 mmol/L for neopterin
and creatinine levels, respectively. Inter- and intra-assay coef-
ficients of variation were 5%.
The study protocol was approved by the Local Ethics Com-
mittee. All subjects gave written informed consent to partici-
pate in the study.
Statistical Analysis
Results are expressed as median and interquartile range
(I–III). Log-transformed values were used for graphic display of
inflammatory mediators. Between-group differences were as-
sessed by nonparametric Mann Whitney U test for continuous
variables and by 2 or Fisher exact test for categorical vari-
ables. Differences of neopterin time course between patient
groups were assessed by nonparametric Friedman test. The
association between a critical t-SOFA score value 10 and
inflammatory parameters was tested by univariable logistic
regression. A two-tailed p value 0.05 was considered statis-
tically significant.
Results
Patient age ranged from 29 to 72 years [median 51 (47–60)].
Sixteen patients had idiopathic dilated cardiomyopathy, 6
ischemic cardiomyopathy (ICM), and 1 acute myocarditis. In
none of the ICM patients was acute decompensation leading to
LVAD implantation triggered by acute myocardial ischemia,
infarction, or postcardiotomy HF. At preimplant, median left
ventricular ejection fraction and t-SOFA values were 20%
(15%–23%) and 6 (5–8), respectively. Of the 23 patients, 8
died because of MOFS at 12 (11–15) days (nonsurvivors),
whereas 15 were alive at 1 month (survivors).
Clinical, hemodynamic, and metabolic parameters at pre-
implant did not differ between survivors and nonsurvivors,
with the exception of age and blood urea nitrogen (BUN)
levels (Table 1). The greater prevalence of ICM among non-
survivors is in agreement with their older age, but this imbal-
ance in ESHF etiology did not achieve statistical significance.
Preimplant two nonsurvivors were supported by extracorpo-
real membrane oxygenation; no other between-group differ-
ence was observed (Table 1).
Preimplant median t-SOFA scores were similar between
survivors [6 (4–7)] and nonsurvivors [6 (5–11)]. Among survi-
vors, 14 continuous axial flow pumps (93%) and 1 continuous
centrifugal LVAD (7%) were implanted; whereas among non-
survivors, 4 continuous axial flow pumps (50%), 3 continuous
centrifugal LVAD (37%), and 1 pulsatile flow pump (13%)
were implanted (p  0.05).
Postoperative Hemodynamic and SOFA Score Profile
Postoperative recovery and hemodynamic improvement
were similar in both groups and were maintained during LVAD
support. Cardiac index improved already at 4 hours after
LVAD implant in both groups [2.75 (2.23–3.25) in survivors vs.
2.80 (2.50–3.20) L  min1  m2 in nonsurvivors; p  0.45].
Likewise, pulmonary capillary wedge pressure at 4 hours post-
LVAD similarly decreased in both groups [7 (7–10) in survivors
vs. 8 (7–12) mm Hg in nonsurvivors, p  0.33). Postoperative
right atrial pressures and inotropic equivalents did not change
compared with preimplant values.
During the first postoperative week, t-SOFA score increased
progressively in both group (p for time0.01), but at 24 hours,
t-SOFA score was persistently higher in nonsurvivors than in
survivors (Figure 1A). In nonsurvivors, t-SOFA peaked at 72
hours, and at this time point, all nonsurvivors and seven sur-
vivors showed t-SOFA score 10, with an overall 65% mor-
tality rate in subjects who reached this score value.
Postoperative Inflammatory Profile
The levels of sCRP, an established marker of inflammation,
paralleled t-SOFA dynamics and peaked at 72 hours (Figure
1B), without any between-group difference.
Pro-inflammatory cytokine levels at preimplant were not different
between survivors and nonsurvivors (Figure 2). Interleukin-6 (Figure
2A) peaked at 4 hours, but between-group differences did not
achieve statistical significance (p  0.065). In addition, TNF-
levels were sustained higher in nonsurvivors than survivors,
with a peak on day 1 (Figure 2B). Interleukin-1 concentra-
tions were higher in nonsurvivors than survivors only on day 7
[13.4 (12.2–22.6) vs. 10.3 (5.5–14.8) pg/ml, respectively, p 
0.045]. InterleukinL-8 concentrations peaked at 4 hours with
significantly sustained higher levels through day 3 in nonsur-
vivors than in survivors (Figure 2C).
Concentrations of the anti-inflammatory mediators IL-1ra (Fig-
ure 3A) and IL-10 (Figure 3B) levels in nonsurvivors also peaked
at 4 hours, were significantly higher than in survivors, and de-
creased to values comparable with those of survivors by day 1.
Neo/Cr, an established marker of monocyte activation, in-
creased progressively only in nonsurvivors (p for time 0.001)
(Figure 4).
Relations Between t-SOFA Score and Early Inflammatory
Response
To assess whether any of the cytokines measured within the
first postimplant 24 hours was predictive of a t-SOFA sugges-
tive of MOFS, we tested by univariable logistic regression pro-
and anti-inflammatory cytokine concentrations obtained at 4
and 24 hours versus the peak t-SOFA score on day 3 hours.
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Only IL-8 levels at 24 hours were significantly associated with
a t-SOFA score 10 at 72 hours (odds ratio 1.10, 95% confi-
dence interval 1.01–1.21, p  0.04) (Figure 5).
Discussion
This study investigated the early pro- and anti-inflammatory
cytokine profiles in LVAD patients and studied their relation-
ship with both t-SOFA score dynamics and MOFS development
during the first postoperative month. The main finding of the
study is that an overactive inflammatory response in the first 2
days and a progressive monocyte activation in the first week
post-LVAD are associated with MOFS development during the
first postoperative month. Patients who developed MOFS showed
a worsening t-SOFA score already in the first days after the peak






(n  8) p
Age, yr 51 (47–60) 48 (45–55) 59 (52–69) 0.02
Male gender, n (%) 21 (91%) 14 (93%) 7 (88%) 1.00
Hypertension, n (%) 3 (13%) 2 (13%) 1 (13%) 1.00
Hyperlipidemia, n (%) 3 (13%) 2 (13%) 1 (13%) 1.00
Diabetes, n (%) 1 (4%) 1 (7%) 0 (0%) 1.00
Etiology, n (%) 0.21
DCM 16 (70%) 12 (80%) 4 (50%)
ICM 6 (26%) 3 (20%) 3 (37%)
Myocarditis 1 (4%) — 1 (13%)
LVEF, % 20 (15–23) 20 (18–24) 17 (15–20) 0.09
MAP, mm Hg 75 (69–82) 75 (71–84) 69 (63–76) 0.07
RAP, mm Hg 6 (5–11) 6 (5–10) 9 (5–17) 0.27
PCWP, mm Hg 24 (15–28) 22 (15–28) 24 (19–33) 0.51
CI, L  min1  m2 1.62 (1.37–2.08) 1.68 (1.43–1.96) 1.56 (1.33–2.04) 0.78
SvO2, % 55 (49–67) 55 (50–62) 61 (51–70) 0.30
Treatments, n (%) 0.07
Oral therapy 5 (22) 2 (13%) 3 (37%)
Inotropic therapy 7 (30) 6 (40%) 1 (13%)
Inotropic therapy  IABP 9 (39) 7 (47%) 2 (25%)
Inotropic therapy  IABP  ECMO 2 (9) — 2 (25%)
Inotropic equivalents, n 8 (3–13) 8 (3–11) 11 (0–16) 0.77
Pre-LVAD IABP support, d 0 (0–5) 0 (0–6) 2 (0–5) 0.92
Surgery time, min 290 (240–365) 325 (240–370) 258 (209–368) 0.32
CPB time, min 90 (78–103) 95 (80–118) 82 (17–91) 0.08
ACC treatment, n (%) 12 (52) 8 (53) 4 (50) 0.38
ACC time, min 46 (37–54) 50 (42–59) 39 (22–45) 0.39
Creatinine, mg/dl 1.18 (0.96–1.60) 1.11 (0.91–1.36) 1.47 (1.04–1.63) 0.17
BUN, mg/dl 58 (39–74) 44 (35–64) 74 (60–98) 0.01
t-Bil, mg/dl 1.43 (0.67–2.26) 1.43 (0.72–1.94) 1.49 (0.80–2.44) 0.68
Data are expressed as median and interquartile range (I–III) or n (%).
ACC, aortic cross-clamp; t-Bil, total bilirubin; BUN, blood urea nitrogen; CI, cardiac index; CPB, cardiopulmonary bypass; DCM, dilated
cardiomyopathy; ECMO, extracorporeal membrane oxygenation; IABP, intraortic balloon pump; ICM, ischemic cardiomyopathy; LVEF, left
ventricular ejection fraction; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SvO2,
mixed venous oxygen saturation.
Figure 1. Panel time course of the total Sequential Organ Failure Assessment (t-SOFA) score (A) and serum C-reactive protein (sCRP) (B)
after LVAD implant in survivors (empty box plots) and nonsurvivors (dark box plots). p values are for differences between groups at each time
point.
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acute inflammatory response, whereas IL-8 levels on day 1 were
associated with a critical t-SOFA value on day 3.
Left ventricular assist device implant has become an effec-
tive therapeutic option for treatment of deteriorating HT can-
didates. Although scoring systems have been developed to
ameliorate risk stratification of ESHF patients candidate to
LVAD implant,9 prediction of MOFS during the first postoper-
ative month is still a challenge. The impact of MOFS on the risk
of ICU mortality after cardiac surgery4,5 has been described by
the use of models purposely developed to measure its dynam-
ics, such as the SOFA system, a six-organ dysfunction/failure
score.4 In our study population, preimplant t-SOFA scores
were similar between nonsurvivors and survivors, whereas
SOFA dynamics in nonsurvivors worsened early after 24–72
hours of ICU stay. These data suggest that inflammatory mech-
anisms leading to MOFS were already activated at that time.
In critically ill patients, differences in mortality were better
predicted by the maximal t-SOFA in the first days of ICU stay.10
total Sequential Organ Failure Assessment higher than 10 or 11
have been associated with elevated mortality rates (10). Ac-
cordingly, in all our nonsurvivors, the peak t-SOFA score on
day 3 was 10.
Figure 2. Time course of logarithmically transformed plasma interleukin (IL)-6 (A), tumor necrosis factor- (TNF-) (B), and IL-8 (C) levels
after left ventricular assist device implant in survivors (empty box plots) and nonsurvivors (dark box plots). p values are for differences
between groups at each time point.
Figure 3. Time course of logarithmically transformed plasma interleukin (IL)-1ra (A) and IL-10 (B) levels after left ventricular assist device
implantation in survivors (empty box plots) and nonsurvivors (dark box plots). p values are for differences between groups at each time point.
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Previous studies reported that LVAD implant induces a re-
lease of pro-inflammatory cytokines.11,12 Left ventricular assist
device patients, deceased of MOFS during the first 3 postop-
erative months, had higher postoperative CRP, IL-6, and IL-8
levels than survivors.6 In our series, simultaneous release of
peculiar inflammatory mediators was observed already at 4
hours after pump activation. Corry et al.11 and Rothenburger et
al.12 also found in event-free LVAD recipients an increase in
IL-6 and IL-8 levels during the first postoperative hours similar
to that observed in ours. Conversely, the exacerbated release
of IL-8 and anti-inflammatory cytokines found in our nonsur-
vivors compared with survivors, suggestive of an overactive
inflammatory status, had not yet been reported. In fact, previ-
ous studies6,13 performed blood sampling for inflammatory
mediators in a more advanced postoperative phase and fur-
thermore described patients who developed MOFS after the
first month postimplant.
Moreover, IL-8 and anti-inflammatory cytokines in our non-
survivors peaked before t-SOFA increment and were more
strictly related to outcome than sCRP, routinely employed for
inflammatory monitoring of LVAD recipients. These data un-
derscore the critical role of early IL-8, IL-10, and IL1-ra release
on the development of MOFS in LVAD recipients during the
first month.
Previous studies reported that high IL-6, IL-8, and TNF levels are
associated with severe MOFS and often precede its development in
cardiogenic shock or trauma patients.7,14,15 Interleukin-6 and
mediators of the immune response were shown to increase
early after cardiovascular surgery in patients who experienced
postoperative MOFS.16 An increase of anti-inflammatory cyto-
kine IL-1ra and IL-10, in addition to uncontrolled release of
pro-inflammatory mediators, was proposed as a peculiar pat-
tern of inflammatory response related to the magnitude of
MOFS development in the setting of trauma and severe acute
pancreatitis.7,8 The simultaneous elevated release of pro- and
anti-inflammatory cytokines might be an index of immunopa-
ralysis, deregulated inflammatory activation leading to cellular
and humoral dysfunction and reduced immune compe-
tence,8,17,18 conditions that favor the development of organ
failure. From our preliminary observations, IL-8, IL-10, and
IL-1ra assessment 24 hours postimplant holds promise as a
potential biochemical predictors of MOFS later on during ICU
stay.
In our experience, the early inflammatory response observed
in nonsurvivors was not correlated to preimplant cytokine
levels or to HF etiology. Older age and higher BUN values,
which reflect long-standing heart failure, renal impairment, and
catabolic disorder, emerged as the only preimplant factors related
to adverse outcome. A deregulated cytokine response was previ-
ously reported in chronic HF patients with co-occurring renal
dysfunction,19 as evidenced by elevated BUN levels. Aging has
been associated with deterioration of the immunoinflamma-
tory system and chronic inflammatory conditions.20 Sandner et
al.21 observed that ESHF patients who developed post-LVAD
renal failure were older and had greatly increased overall
mortality compared with subjects who did not have renal
failure. Because LVAD implant has been described to deter-
mine an aberrant activation of T cells and monocytes,22 which
are a major source of pro-inflammatory cytokines IL-6 and
IL-8, we suppose that our elderly LVAD patients with elevated
preimplant BUN were probably more susceptible to develop
MOFS by an early overactive and deregulated inflammatory
response probably linked to LVAD-induced monocyte or T
cells hyperactivity present at preimplant.
The higher prevalence of continuous axial flow pumps
than continuous centrifugal and pulsatile flow pumps in
survivors versus nonsurvivors hints to a lesser impact of the
former LVAD type on the development of an early exacer-
bated inflammatory response and worsening of t-SOFA sta-
tus. However, the limited number of patients implanted with
continuous centrifugal and pulsatile flow pumps and the
nonrandomized nature of our observations mandate caution
in interpreting this finding.
The early rise of IL-8, IL-10, and IL-1ra, limited to the first
hours after LVAD implantation, could play a critical role in the
activation of a downstream inflammatory pathway. This hy-
pothesis is reinforced by the observed IL-1 and TNF- release
and monocyte activation, temporally correspondent to t-SOFA
increment later on in our nonsurvivors, which point to a
crucial role of these parameters in MOFS development.
Indeed, TNF- is mainly produced from the monocyte/macro-
phage lineage and is recognized as the pivotal cytokine re-
sponsible for the clinical manifestations of shock leading to
systemic inflammatory response syndrome after sepsis.7 Simi-
larly, IL-1 is a major product of activated human monocytes,
Figure 4. Time course of urine Neo/Cr levels after left ventricular
assist device implantation in survivors (empty box plots) and non-
survivors (dark box plots).
Figure 5. Logarithmically transformed plasma interleukin (IL)-8
concentrations at day 1 are plotted against total Sequential Organ
Failure Assessment (t-SOFA) at day 3 (see text).
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tissue macrophages, and neutrophils and shares many of the
TNF- inflammatory properties.
As observed in severe sepsis and septic shock, the predom-
inant mechanisms leading to the development of MOFS are
microcirculatory dysfunction and cytopathic tissue hypoxia
associated to an unbalanced inflammatory response.23 In
LVAD patients developing MOFS, hepatic microcirculation
dysfunction and presence of intravascular coagulation, prob-
ably due to monocyte and endothelial activation, were ob-
served.6,24 Therefore, a deregulated inflammatory response in
the early post-LVAD phase, as observed in our nonsurvivors,
might reflect a key signal activating the biological mechanisms
leading to MOFS.
Whether therapeutic interventions to block this hyperinflam-
matory response may decrease the incidence of MOFS in LVAD
recipients remains to be established with an appropriate interven-
tional study. Putative treatments targeted at correcting these
mechanisms in the preimplant phase are the intravenous admin-
istration of free radical scavenging agent, such as N-acetylcyste-
ine, in view of its anti-inflammatory and antioxidant effects ob-
served in a wide range of clinical applications,25,26 as well as
intermittent hemofiltration, which has been shown to reduce the
elevated circulating levels of IL-8 and monocyte chemoattractant
protein-1 in congestive heart failure patients.27
Conclusion
Our study indicates that an early release of pro- and anti-
inflammatory cytokines after LVAD implant parallels an in-
creased t-SOFA in the first days of LVAD support is related to
MOFS development during the first postoperative month. Al-
though our findings require validation in a larger patient
population, the combined evaluation of early inflammatory
profile, in particular IL-8 level at 24 hours and IL-10 and IL-1ra
levels at 4 hours, and t-SOFA score seems a potential tool to
identify those patients prone to develop MOFS and to guide
clinical decision making early after LVAD implant.
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